vs

Side-by-side financial comparison of ACACIA RESEARCH CORP (ACTG) and Bioceres Crop Solutions Corp. (BIOX). Click either name above to swap in a different company.

Bioceres Crop Solutions Corp. is the larger business by last-quarter revenue ($77.6M vs $50.1M, roughly 1.5× ACACIA RESEARCH CORP). ACACIA RESEARCH CORP runs the higher net margin — 6.8% vs -9.6%, a 16.4% gap on every dollar of revenue. On growth, ACACIA RESEARCH CORP posted the faster year-over-year revenue change (2.6% vs -16.8%). Over the past eight quarters, ACACIA RESEARCH CORP's revenue compounded faster (43.6% CAGR vs -8.4%).

Acacia Research Corporation is a publicly traded American company based in New York City. It acquires and operates businesses in industries including the technology, energy, and industrial/manufacturing sectors. Acacia has a strategic relationship with Starboard Value, LP, the company's controlling shareholder. The company has been characterized as a patent troll.

Bioceres Crop Solutions Corp is a global agricultural technology firm that develops and commercializes sustainable crop solutions including drought-tolerant seed traits, biofertilizers, and biopesticides. It serves farmers across South America, North America, Europe and Asia-Pacific, focusing on raising crop yields while reducing the environmental footprint of agricultural activities.

ACTG vs BIOX — Head-to-Head

Bigger by revenue
BIOX
BIOX
1.5× larger
BIOX
$77.6M
$50.1M
ACTG
Growing faster (revenue YoY)
ACTG
ACTG
+19.4% gap
ACTG
2.6%
-16.8%
BIOX
Higher net margin
ACTG
ACTG
16.4% more per $
ACTG
6.8%
-9.6%
BIOX
Faster 2-yr revenue CAGR
ACTG
ACTG
Annualised
ACTG
43.6%
-8.4%
BIOX

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
ACTG
ACTG
BIOX
BIOX
Revenue
$50.1M
$77.6M
Net Profit
$3.4M
$-7.4M
Gross Margin
12.8%
46.8%
Operating Margin
-26.1%
9.3%
Net Margin
6.8%
-9.6%
Revenue YoY
2.6%
-16.8%
Net Profit YoY
125.5%
-20.2%
EPS (diluted)
$0.03
$-0.12

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ACTG
ACTG
BIOX
BIOX
Q4 25
$50.1M
Q3 25
$59.4M
$77.6M
Q2 25
$51.2M
Q1 25
$124.4M
$60.6M
Q4 24
$48.8M
$98.8M
Q3 24
$23.3M
$93.3M
Q2 24
$25.8M
Q1 24
$24.3M
$84.0M
Net Profit
ACTG
ACTG
BIOX
BIOX
Q4 25
$3.4M
Q3 25
$-2.7M
$-7.4M
Q2 25
$-3.3M
Q1 25
$24.3M
$-1.6M
Q4 24
$-13.4M
$605.2K
Q3 24
$-14.0M
$-6.2M
Q2 24
$-8.4M
Q1 24
$-186.0K
$9.8M
Gross Margin
ACTG
ACTG
BIOX
BIOX
Q4 25
12.8%
Q3 25
21.2%
46.8%
Q2 25
12.8%
Q1 25
47.4%
39.4%
Q4 24
17.6%
42.0%
Q3 24
10.1%
40.2%
Q2 24
26.2%
Q1 24
49.2%
50.8%
Operating Margin
ACTG
ACTG
BIOX
BIOX
Q4 25
-26.1%
Q3 25
-10.8%
9.3%
Q2 25
-24.2%
Q1 25
30.8%
1.5%
Q4 24
-32.4%
14.5%
Q3 24
-44.1%
2.5%
Q2 24
-18.4%
Q1 24
-8.6%
15.7%
Net Margin
ACTG
ACTG
BIOX
BIOX
Q4 25
6.8%
Q3 25
-4.6%
-9.6%
Q2 25
-6.4%
Q1 25
19.5%
-2.6%
Q4 24
-27.5%
0.6%
Q3 24
-60.0%
-6.6%
Q2 24
-32.7%
Q1 24
-0.8%
11.6%
EPS (diluted)
ACTG
ACTG
BIOX
BIOX
Q4 25
$0.03
Q3 25
$-0.03
$-0.12
Q2 25
$-0.03
Q1 25
$0.25
$-0.02
Q4 24
$-0.14
$0.00
Q3 24
$-0.14
$-0.10
Q2 24
$-0.08
Q1 24
$0.00
$0.14

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ACTG
ACTG
BIOX
BIOX
Cash + ST InvestmentsLiquidity on hand
$306.7M
$15.5M
Total DebtLower is stronger
$91.9M
Stockholders' EquityBook value
$543.5M
$288.3M
Total Assets
$771.0M
$734.9M
Debt / EquityLower = less leverage
0.17×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ACTG
ACTG
BIOX
BIOX
Q4 25
$306.7M
Q3 25
$301.8M
$15.5M
Q2 25
$316.7M
Q1 25
$272.0M
$38.5M
Q4 24
$273.9M
$29.2M
Q3 24
$410.9M
$32.3M
Q2 24
$441.9M
Q1 24
$498.4M
$16.4M
Total Debt
ACTG
ACTG
BIOX
BIOX
Q4 25
$91.9M
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
Stockholders' Equity
ACTG
ACTG
BIOX
BIOX
Q4 25
$543.5M
Q3 25
$537.6M
$288.3M
Q2 25
$538.6M
Q1 25
$540.2M
$345.0M
Q4 24
$514.8M
$346.3M
Q3 24
$540.2M
$346.0M
Q2 24
$560.7M
Q1 24
$568.3M
$348.5M
Total Assets
ACTG
ACTG
BIOX
BIOX
Q4 25
$771.0M
Q3 25
$768.9M
$734.9M
Q2 25
$775.5M
Q1 25
$801.6M
$798.2M
Q4 24
$756.4M
$835.2M
Q3 24
$707.6M
$827.3M
Q2 24
$753.6M
Q1 24
$631.7M
$836.1M
Debt / Equity
ACTG
ACTG
BIOX
BIOX
Q4 25
0.17×
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ACTG
ACTG
BIOX
BIOX
Operating Cash FlowLast quarter
$75.2M
$14.4M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
22.01×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ACTG
ACTG
BIOX
BIOX
Q4 25
$75.2M
Q3 25
$9.5M
$14.4M
Q2 25
$50.1M
Q1 25
$2.4M
$23.3M
Q4 24
$50.1M
$-5.4M
Q3 24
$-593.0K
$5.2M
Q2 24
$16.1M
Q1 24
$54.8M
$-17.4M
Free Cash Flow
ACTG
ACTG
BIOX
BIOX
Q4 25
Q3 25
Q2 25
Q1 25
$335.0K
Q4 24
$-98.5M
Q3 24
$-2.8M
Q2 24
$-126.7M
Q1 24
$54.6M
FCF Margin
ACTG
ACTG
BIOX
BIOX
Q4 25
Q3 25
Q2 25
Q1 25
0.3%
Q4 24
-201.8%
Q3 24
-12.1%
Q2 24
-490.5%
Q1 24
224.4%
Capex Intensity
ACTG
ACTG
BIOX
BIOX
Q4 25
Q3 25
Q2 25
Q1 25
1.7%
Q4 24
304.4%
Q3 24
9.6%
Q2 24
553.0%
Q1 24
1.1%
Cash Conversion
ACTG
ACTG
BIOX
BIOX
Q4 25
22.01×
Q3 25
Q2 25
Q1 25
0.10×
Q4 24
-8.85×
Q3 24
Q2 24
Q1 24
-1.78×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ACTG
ACTG

Energy Operations$16.0M32%
Transportation Safety$10.4M21%
Office Storage And Display Solutions$8.4M17%
Printers Consumables And Parts$6.5M13%
Natural Gas Reserves$5.1M10%
Natural Gas Liquids Reserves$3.3M7%

BIOX
BIOX

Segment breakdown not available.

Related Comparisons